
Please try another search
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Matthew R. Patterson | 51 | 2020 | Independent Chairman of the Board |
Daniella Beckman | 44 | 2020 | Independent Director |
Siddhartha Mukherjee | 54 | - | Scientific Founder & Chairman of Scientific Advisory Board |
Jean-Paul Kress | 60 | 2025 | Chairman & CEO |
Joshua Resnick | 51 | 2019 | Independent Director |
Steven Devine | - | - | Scientific & Clinical Advisor |
Malcolm K. Brenner | 73 | 2023 | Scientific Advisor |
Eric L. Sievers | 61 | - | Scientific & Clinical Advisor |
Robert J. Soiffer | 67 | - | Scientific & Clinical Advisor |
David C. Lubner | 61 | 2020 | Independent Director |
Olivier Danos | 67 | 2021 | Scientific & Clinical Advisor |
Hans-Peter Kiem | - | - | Scientific & Clinical Advisor |
Soheil Meshinchi | - | 2021 | Scientific & Clinical Advisor |
Pietro Genovese | - | 2023 | Scientific Advisor |
Erez Charnes Kalir | - | 2025 | Independent Director |
Fouad Namouni | 56 | 2024 | Independent Director |
Michel Detheux | 59 | 2025 | Director |
Saar Gill | - | 2023 | Scientific Advisor |
Alexander G. Cumbo | 54 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review